Search
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant.
Synonyms: 2-((2-Ethoxyphenoxy)methyl)morpholineCategories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesEquine Botulinum Neurotoxin A Immune FAB2
go.drugbank.com/drugs/DB13900ApprovedEquine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.
Synonyms: Botulinum Neurotoxin A immune FAB2 (equine), BOTULINUM NEUROTOXIN A IMMUNE FAB2, EQUINERegorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases. … It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalResmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Synonyms: 1,2,4-Triazine-6-carbonitrile, 2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-, 2-[3,5-Dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrileCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingTafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigationalTafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.
Categories: Lymphoma, B-CellMidazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigationalMidazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. … [A257153] Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.[L5074]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: MIDAZOLAM5 MG /ML X 3 ML, N/aCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTASAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalAprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan]. … blocker, and a diuretic at maximally tolerated doses.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2C18 InhibitorsTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. … [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalis a major known risk factor for CVD. … Inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density
Categories: Compounds used in a research, industrial, or household setting, Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET